Cbl-3 Inhibitors

Chemical inhibitors of Cbl-3 function by interfering with the signaling pathways and enzymatic activities that are crucial for its role as an E3 ubiquitin-protein ligase. Imatinib, Dasatinib, Nilotinib, Ponatinib, and Bosutinib are tyrosine kinase inhibitors that can prevent the phosphorylation of proteins that would typically be recognized and ubiquitinated by Cbl-3, thus inhibiting its ability to tag these substrates for degradation. The inhibition of ABL kinase by Imatinib and Nilotinib, as well as Src family kinases by Dasatinib and Bosutinib, disables the phosphorylation-dependent signaling events that are necessary for the full activation of Cbl-3. Similarly, Ponatinib's broad-spectrum kinase inhibition includes ABL, which is essential for the recruitment and proper functioning of Cbl-3 in cellular signaling.

Sorafenib and Sunitinib, as multi-targeted receptor tyrosine kinase inhibitors, can disrupt the phosphorylation cascades that Cbl-3 is a part of. By blocking these kinases, these inhibitors can limit the availability of active phosphorylated substrates for Cbl-3, thus reducing its ubiquitination activity. Erlotinib and Gefitinib specifically inhibit the epidermal growth factor receptor (EGFR), a known substrate of Cbl-3, which hampers the receptor's internalization and degradation process mediated by Cbl-3. By preventing the activation of EGFR, Erlotinib and Gefitinib indirectly impair the ability of Cbl-3 to ubiquitinate and regulate the turnover of this receptor. Lapatinib extends this inhibitory effect to HER2 as well as EGFR, further broadening the scope of inhibition against Cbl-3's substrate receptors. Vandetanib's inhibition of VEGFR, EGFR, and RET can lead to a decrease in Cbl-3-mediated ubiquitination of these kinases, thus disrupting the signaling pathways that rely on Cbl-3 for receptor turnover and downregulation. Lastly, Crizotinib, by inhibiting c-Met and ALK, can alter the interaction between these kinases and Cbl-3, potentially impairing the ubiquitination and degradation of the receptors that Cbl-3 targets.